22nd January 2019 – Leading Australian medicinal cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to announce its DayaCann joint venture is to commence its first third party cannabis cultivation activity with Khiron Life Sciences Corp (TSXv:KHRN) (‘Khiron’).
Khiron is a Canadian listed medicinal cannabis company with core operations in Colombia. AusCann announced an MoU between DayaCann and Khiron on 1 October 2018 to collaborate on the development of medicinal cannabis products and market in Chile. This includes cultivation, manufacturing, scientific and commercial activities that support cannabinoid medicines as a valued medicinal option.
For further information please download PDF attached:
Download this document
